Caremark wins partial dismissal while Rxeed interference claim survives
A New York federal judge dismissed Rxeed's antitrust and contractual-interference claims against Caremark. A claim concerning prospective business relationships remains pending.
U.S. District Judge Jessica G. L. Clarke issued a mixed ruling on September 29, 2026, in Rxeed, LLC v. Caremark, LLC, No. 7:26-cv-00331, Southern District of New York. Document 40 dismissed two claims while allowing one to proceed.
Rxeed alleged Caremark rejected purchase histories generated through its prescription-drug marketplace, damaging relationships with pharmacies. It sought more than $2 million in lost revenue. The amount was not awarded.
The judge dismissed the New York Donnelly Act claim because Rxeed had not adequately alleged multilateral anticompetitive conduct. A contractual-interference claim also failed, while the claim for interference with prospective economic advantage survived.
The parties were directed to propose a case-management plan by October 20, with an initial conference scheduled for October 27. The decision is not a liability verdict or government enforcement action.
Cite this report
The Precedent. "Caremark wins partial dismissal while Rxeed interference claim survives." October 1, 2026. https://theprecedent.org/article/caremark-wins-partial-dismissal-while-rxeed-interference-claim-survives
